Pharma industry files investment intentions of Rs. 12,655 crore in first 11 months of 2021

Gireesh Babu, New DelhiSaturday, January 22, 2022, 08:00 Hrs  [IST]

The investment sentiment in the drugs and pharmaceuticals industry has been on upbeat during the year 2021, as the sector has witnessed the investment intentions for the first 11 months of the year which is a little less than the total investment intentions filed both in 2019 and 2020, according to official data.

According to the data released by the Department for Promotion of Industry and International Trade (DPIIT), drugs and pharmaceuticals industry has filed 71 Industrial Entrepreneurs Memorandums (IEMs) - which indicates the investment intentions of the industry - with cumulative proposed investment of around Rs. 12,655 crore from January to November, 2021.

During the 12 months of the year 2020, the sector has seen 77 IEMs filed with proposed investment of around Rs. 7,376 crore, and in the year 2019, this was 87 IEMs with investment intentions to the tune of Rs. 8,534 crore. While the Covid-19 has raised challenges to the healthcare and pharmaceutical industries from 2020, the investment intentions show that the sentiment towards investment has been high during the year 2021.

Interestingly, data shows that the October and November months have reported a total of Rs. 3,890 crore of IEMs from the drugs and pharmaceutical industries. The IEMs filed from January to September were a total of Rs. 8,765 crore, as reported earlier.

It may be noted that the government has also announced various production linked incentive (PLI) schemes for bulk drugs, intermediates and formulations sector, in order to strengthen manufacturing in the country for self sustenance and to reduce dependence on China for many of the active ingredients and intermediates, in 2020 and 2021. The PLI schemes announced in 2021 were well received by the industry.

Some of the major IEMs filed in the sector during the month of November include proposed investment by Maharashtra-based Reliance Life Sciences Pvt Ltd for rituximab 100 mg and 500 mg (4 lakh vials/PF), Hyderabad-based Neuland Laboratories Ltd for anti-fungal drug ibrexafungerp citrate (2000 kgs), Mumbai-based IPCA Laboratories for chloroquine phosphate (200 MTA), Chennai-based Malladi Drugs and Pharmaceuticals for methadone (1000 kilos), Hyderabad-based Hetero Biopharma Ltd for biosimilar products (1 crore numbers), Bengaluru-based Neoanthem Lifesciences for manufacture of peptides like plecanatide, semaglutide, liraglutide and others (1.05 lakh kilogram) among others.

The investment intentions into the medical and surgical instruments industry has reported a growth with nine IEMs worth Rs. 556 crore being reported for the first 11 months of 2021. This is compared to the nine IEMs worth Rs. 467 crore reported in 12 months of 2020 and three IEMs worth Rs. 167 crore reported during the 12 months of 2019.

However, in terms of IEM forms filed by the entrepreneurs to report the IEMs implemented shows that the investments implemented during the 11 months till November 2021, was of Rs. 3,540 crore in 29 IEMs. This is against Rs. 5,599 crore in 39 IEMs implemented and reported in 12 months of 2020 and Rs. 4,854 crore in 36 IEMs in 2019. According to sources, the investment made during the year could be higher, as some investors may not update the Part B of the IEM form to report the IEMs implemented.

In terms of investments implemented during January to November, 2021 in the medical and surgical instruments sector was two IEMs with an investment of Rs. 213 crore, as compared to one IEM and Rs. 13 crore investment in the 12 months of previous year.